No Data
He Yu-B (02256.HK): Tang Yanmin resigned as Non-Executive Director.
On December 20, 2023, Ge Long Hui announced that Ms. Tang Yanmin will resign from her position as a non-executive Director on December 20, 2024, as she needs to devote more energy to handle other work. After her resignation, she will no longer hold any position in the company.
[Brokerage Focus] Guoyuan International: He Yu (02256) is currently severely undervalued, and the long-term development prospects are Bullish.
Jinwu Finance News | Guoyuan International Research points out that Heyu (02256) has announced that its independently developed highly selective small molecule FGFR4 inhibitor, Ipagoatinib (ABSK011), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China to conduct a registration clinical study for the treatment of hepatocellular carcinoma (HCC). The agency indicates that this approved registration clinical study is a multicenter, randomized, double-blind study that evaluates the efficacy of Ipagoatinib combined with best supportive care (BSC) versus placebo combined with BSC in patients who have undergone immune checkpoint inhibitors (ICI) and multi-targeted tyrosine kinase inhibitors.
Hong Kong stocks moving | He Yu-B (02256) rose nearly 4% after receiving CDE approval to conduct registrational clinical research on ipatasertib for the treatment of hepatocellular carcinoma.
He Yu-B (02256) rose nearly 4%, as of the time of writing, it increased by 3.78% to 4.67 Hong Kong dollars, with a transaction volume of 5.3773 million Hong Kong dollars.
Notice highlights | China Eastern Airlines Corporation's passenger traffic increased by about 20% in November; CTIHK expects an annual Net income growth of no less than 30%.
In November, CHINA SOUTH AIR's passenger capacity input rose by 7.18% year-on-year; passenger turnover increased by 15.17% year-on-year; China Eastern Airlines' passenger capacity input increased by 9.19% year-on-year; passenger turnover increased by 20.86% year-on-year.
Hong Kong Stock Announcement Glimpse | Huaxin Cement intends to invest approximately 0.1866 billion USD to acquire four aggregate plants in Brazil.
SSY GROUP (02005): Fumaric acid volnorex and Dronedarone hydrochloride have been approved for registration by the National Medical Products Administration for use as Active Pharmaceutical Ingredient in marketed formulations; GRANDPHARMA (00512): The Global innovative treatment product for demodex blepharitis has had its marketing license application accepted by the China National Medical Products Administration.
Express News | Abbisko Cayman - Cde Approval to Initiate Registrational Clinical Study of Irpagratinib (Absk011) in Patients With Hcc
